TACSTD2 and liver cancer: Moreover, TACSTD2-high liver cancer possessed fewer CTNNB1 mutations, which are a biomarker for poor ICI response and are associated with an immune “cold” microenvironment.26,27 No difference in post-ICI response when segmenting by TACSTD2-high versus TACSTD2-low was observed even when looking at CTNNB1 wild-type and mutant tumors separately (data not shown).